In a unanimous ruling Monday, the Supreme Court has paved the way for more accessible cutting edge medicine. The ruling speeds up the time for generic biotech drugs to become available to the public.
Novartis, a Swiss-based pharmaceutical company, will now be allowed to sell their generic version of California-based Amgen's cancer drug, Neupogen; without having to wait the standard six months after FDA approval. A law created in 2010 allows for cheaper generics, called biosimilars, to be produced after a 12-year exclusive run for the original.
Biologic drugs are derived from living cells instead of chemicals and are designed to surpress specific components of the immune system to treat diseases like cancer and rheumatoid arthritis.
The implications of the ruling are substantial to say the least. Even six months of shelf time can account for billions of dollars for the pharmaceutical companies. What it will also mean is that more sick people will have access to higher quality medical treatments without going into crippling debt.
I'm busy working on my blog posts. Watch this space!
Evil But Not Illegal, Experts Say
July 25, 2017
It's Currently Illegal to Run Your Vehicle Unattended in Michigan
June 13, 2017
Homeless Facing Fines up to $500 and 6 Months in Jail